Highlights

2000 - 2007

2000 : Ascend is organized and begins its work developing products.

2007 : Ascend receives its first independent approval for the product Benzonatate.

2008 - 2010

2008 : Ascend launches its own label into the market.

2010 : Ascend meets and partners with Alkem.

2012 - 2015

2012 : Ascend sells outstanding shares to Alkem and becomes US subsidiary.

2014 : Alkem/Ascend receives first exclusive generic approval from FDA on Mycophenolate Suspension.

2015 : Alkem/Ascend acquires Norac, a DEA API manufacturer in Azusa , CA.

2016

Alkem/Ascend acquires Long Pharma in Fenton Mo. Long is the prior Fleming facility for Finished Dose Formulation work.